A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Clinical trial NCT06930794 · RECRUITING

Trial details

NCT number: NCT06930794
Sponsor: Beijing Pearl Biotechnology Limited Liability Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-07-07
Primary completion: 2029-02-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.